Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study-Reference-Cited by-同舟云学术

Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study

Published:2018-10-30 Issue:1 Volume:58 Page:110-118
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Thomsen Frederik Birkebæk¹,Bosco Cecilia²,Garmo Hans²³^ORCID,Adolfsson Jan⁴,Hammar Niklas⁵⁶,Stattin Pär⁷,Van Hemelrijck Mieke²⁵

Affiliation:

1. Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark;

2. Translational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King’s College London, London, UK;

3. Regional Cancer Centre Uppsala Örebro, Uppsala University Hospital, Uppsala, Sweden;

4. CLINTEC-department, Karolinska Institutet, Stockholm, Sweden;

5. Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden;

6. Medical Evidence and Observational Research, Global Medicines Development, AstraZeneca, Stockholm, Sweden;

7. Department of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden

Publisher

Informa UK Limited

Subject

Radiology Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2018.1529427

Reference33 articles.

1. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer

2. Diagnosis, referral, and primary treatment decisions in newly diagnosed prostate cancer patients in a multidisciplinary diagnostic assessment program

3. Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2007 and 2013: status from a Danish primary referral center

4. Patterns of androgen deprivation therapies among men diagnosed with localised prostate cancer: A population-based study

5. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reporting of Observational Studies Explicitly Aiming to Emulate Randomized Trials;JAMA Network Open;2023-09-27

2. Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14);Acta Oncologica;2023-04-03

3. Use of Propensity Scoring and Its Application to Real‐World Data: Advantages, Disadvantages, and Methodological Objectives Explained to Researchers Without Using Mathematical Equations;The Journal of Clinical Pharmacology;2021-11-24

4. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer;European Urology;2019-04